JP2010502591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010502591A5 JP2010502591A5 JP2009526263A JP2009526263A JP2010502591A5 JP 2010502591 A5 JP2010502591 A5 JP 2010502591A5 JP 2009526263 A JP2009526263 A JP 2009526263A JP 2009526263 A JP2009526263 A JP 2009526263A JP 2010502591 A5 JP2010502591 A5 JP 2010502591A5
- Authority
- JP
- Japan
- Prior art keywords
- active agent
- core
- layer
- polymer
- polymer layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000010410 layer Substances 0.000 claims 52
- 239000013543 active substance Substances 0.000 claims 44
- 229920000642 polymer Polymers 0.000 claims 31
- 239000000463 material Substances 0.000 claims 15
- 239000011796 hollow space material Substances 0.000 claims 14
- 239000011248 coating agent Substances 0.000 claims 11
- 238000000576 coating method Methods 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- -1 polyoxyethylene Polymers 0.000 claims 8
- 229920001577 copolymer Polymers 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229920002678 cellulose Polymers 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 210000004051 gastric juice Anatomy 0.000 claims 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 4
- 239000001856 Ethyl cellulose Substances 0.000 claims 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 3
- 239000001913 cellulose Substances 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims 3
- 229920001249 ethyl cellulose Polymers 0.000 claims 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims 3
- 239000000194 fatty acid Substances 0.000 claims 3
- 229930195729 fatty acid Natural products 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- 238000007726 management method Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 210000002784 stomach Anatomy 0.000 claims 3
- 238000010521 absorption reaction Methods 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 229920002301 cellulose acetate Polymers 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- 235000010755 mineral Nutrition 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000003637 steroidlike Effects 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 1
- CAVQBDOACNULDN-NRCOEFLKSA-N (1s,2s)-2-(methylamino)-1-phenylpropan-1-ol;sulfuric acid Chemical compound OS(O)(=O)=O.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 CAVQBDOACNULDN-NRCOEFLKSA-N 0.000 claims 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical compound OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- 206010000599 Acromegaly Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 108010039627 Aprotinin Proteins 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 108010061435 Enalapril Proteins 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 239000005639 Lauric acid Substances 0.000 claims 1
- 108010000817 Leuprolide Proteins 0.000 claims 1
- 108010007859 Lisinopril Proteins 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 229920001800 Shellac Polymers 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 229920002494 Zein Polymers 0.000 claims 1
- 229940081735 acetylcellulose Drugs 0.000 claims 1
- 229960004150 aciclovir Drugs 0.000 claims 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 1
- 229920006243 acrylic copolymer Polymers 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 229920013820 alkyl cellulose Polymers 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 239000002269 analeptic agent Substances 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003266 anti-allergic effect Effects 0.000 claims 1
- 230000001088 anti-asthma Effects 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 230000001384 anti-glaucoma Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 229940035678 anti-parkinson drug Drugs 0.000 claims 1
- 230000002785 anti-thrombosis Effects 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000000939 antiparkinson agent Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 239000003699 antiulcer agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229960004405 aprotinin Drugs 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 229960000794 baclofen Drugs 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 229960004530 benazepril Drugs 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- 229960000997 bicalutamide Drugs 0.000 claims 1
- 239000003833 bile salt Substances 0.000 claims 1
- 229940093761 bile salts Drugs 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims 1
- 229960004195 carvedilol Drugs 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 229940127243 cholinergic drug Drugs 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940124558 contraceptive agent Drugs 0.000 claims 1
- 239000003433 contraceptive agent Substances 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 229920006237 degradable polymer Polymers 0.000 claims 1
- 229960003964 deoxycholic acid Drugs 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 229960000633 dextran sulfate Drugs 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 1
- 229960000873 enalapril Drugs 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 229960004667 ethyl cellulose Drugs 0.000 claims 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims 1
- 229960001596 famotidine Drugs 0.000 claims 1
- 150000002191 fatty alcohols Chemical class 0.000 claims 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 1
- 229960002297 fenofibrate Drugs 0.000 claims 1
- 239000002871 fertility agent Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000004083 gastrointestinal agent Substances 0.000 claims 1
- 229940127227 gastrointestinal drug Drugs 0.000 claims 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims 1
- 229960001381 glipizide Drugs 0.000 claims 1
- 125000005908 glyceryl ester group Chemical group 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 239000003326 hypnotic agent Substances 0.000 claims 1
- 230000000147 hypnotic effect Effects 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 1
- 229960004338 leuprorelin Drugs 0.000 claims 1
- 229960002394 lisinopril Drugs 0.000 claims 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 1
- 229960003088 loratadine Drugs 0.000 claims 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 claims 1
- 239000003695 memory enhancer Substances 0.000 claims 1
- 229940041616 menthol Drugs 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000003232 mucoadhesive effect Effects 0.000 claims 1
- 239000003149 muscarinic antagonist Substances 0.000 claims 1
- 229940035363 muscle relaxants Drugs 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 229920005615 natural polymer Polymers 0.000 claims 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims 1
- 229960001800 nefazodone Drugs 0.000 claims 1
- 229960001597 nifedipine Drugs 0.000 claims 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical group CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 claims 1
- 229960000965 nimesulide Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229940127073 nucleoside analogue Drugs 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 1
- 239000000734 parasympathomimetic agent Substances 0.000 claims 1
- 230000001499 parasympathomimetic effect Effects 0.000 claims 1
- 229940005542 parasympathomimetics Drugs 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 239000004584 polyacrylic acid Substances 0.000 claims 1
- 239000013047 polymeric layer Substances 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 229960004159 pseudoephedrine sulfate Drugs 0.000 claims 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims 1
- 229960000620 ranitidine Drugs 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 229940125723 sedative agent Drugs 0.000 claims 1
- 239000004208 shellac Substances 0.000 claims 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 1
- 229940113147 shellac Drugs 0.000 claims 1
- 235000013874 shellac Nutrition 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 claims 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 229960004025 sodium salicylate Drugs 0.000 claims 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229920001059 synthetic polymer Polymers 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 229960004380 tramadol Drugs 0.000 claims 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 1
- 239000003204 tranquilizing agent Substances 0.000 claims 1
- 230000002936 tranquilizing effect Effects 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
- 229920006163 vinyl copolymer Polymers 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 239000001993 wax Substances 0.000 claims 1
- 239000005019 zein Substances 0.000 claims 1
- 229940093612 zein Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1411MU2006 | 2006-09-04 | ||
| PCT/IN2007/000392 WO2008062440A2 (en) | 2006-09-04 | 2007-09-03 | Programmable buoyant delivery technology |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010502591A JP2010502591A (ja) | 2010-01-28 |
| JP2010502591A5 true JP2010502591A5 (enExample) | 2010-10-14 |
Family
ID=39430167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009526263A Pending JP2010502591A (ja) | 2006-09-04 | 2007-09-03 | プログラム可能な浮揚性送達技術 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8277843B2 (enExample) |
| EP (1) | EP2068844A4 (enExample) |
| JP (1) | JP2010502591A (enExample) |
| KR (1) | KR20090065524A (enExample) |
| CN (1) | CN101511346B (enExample) |
| AR (1) | AR062644A1 (enExample) |
| AU (1) | AU2007323018B2 (enExample) |
| BR (1) | BRPI0716481A2 (enExample) |
| CA (1) | CA2661172A1 (enExample) |
| CL (1) | CL2007002562A1 (enExample) |
| IL (1) | IL197121A0 (enExample) |
| MX (1) | MX2009002371A (enExample) |
| NO (1) | NO20090807A (enExample) |
| RU (1) | RU2420268C2 (enExample) |
| WO (1) | WO2008062440A2 (enExample) |
| ZA (1) | ZA200901162B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
| WO2009153635A1 (en) * | 2008-06-19 | 2009-12-23 | University Of Witwatersrand, Johannesburg | A chronotherapeutic pharmaceutical dosage form |
| ZA200903858B (en) * | 2008-06-19 | 2013-10-30 | Univ Of Witwatesrand Johannesburg | Pharmaceutical dosage form |
| CA2638240C (en) * | 2008-08-29 | 2010-02-02 | Alexander Macgregor | Method of treating dysglycemia and glucose excursions |
| CA2767143A1 (en) * | 2009-07-06 | 2011-01-13 | Kyorin Pharmaceutical Co., Ltd. | Tablet having hollow structure |
| US8901113B2 (en) | 2009-09-30 | 2014-12-02 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
| US20110177231A1 (en) * | 2010-01-16 | 2011-07-21 | Alexander Grinberg | Nano-, Micro-, Macro- Encapsulation And Release Of Materials |
| US20110200671A1 (en) * | 2010-02-17 | 2011-08-18 | Sun Pharma Advanced Research Company Ltd. | Method of treating a disease condition susceptible to baclofen therapy |
| EP2415460A1 (de) * | 2010-08-03 | 2012-02-08 | ratiopharm GmbH | Orale Darreichungsform von Pregabalin |
| GB201102148D0 (en) | 2011-02-08 | 2011-03-23 | Ucl Business Plc | Layered bodies, compositions containing them and processes for producing them |
| BR112014000773A8 (pt) * | 2011-07-14 | 2017-10-03 | Apet Holding B V | Composições de nicotinamida e uso terapêutico das mesmas |
| ES2691982T3 (es) | 2012-11-30 | 2018-11-29 | Acura Pharmaceuticals, Inc. | Liberación autorregulada de un principio activo farmacéutico |
| US8859005B2 (en) | 2012-12-03 | 2014-10-14 | Intercontinental Great Brands Llc | Enteric delivery of functional ingredients suitable for hot comestible applications |
| KR102241487B1 (ko) | 2013-02-20 | 2021-04-16 | 주식회사 종근당 | 제어방출 펠릿으로 된 약제학적 조성물 |
| US20160242632A1 (en) * | 2013-10-22 | 2016-08-25 | Ganyu Lu | System and Method for Capsule Device with Multiple Phases of Density |
| WO2015145461A1 (en) | 2014-03-26 | 2015-10-01 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent immediate release biphasic matrix solid dosage form |
| CN106714893B (zh) | 2014-06-11 | 2021-01-01 | 麻省理工学院 | 自组装的驻留装置及相关方法 |
| US20170266112A1 (en) | 2014-06-11 | 2017-09-21 | Massachusetts Institute Of Technology | Residence structures and related methods |
| WO2017040607A1 (en) | 2015-08-31 | 2017-03-09 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
| HK1258050A1 (zh) | 2015-10-23 | 2019-11-01 | Lyndra Therapeutics, Inc. | 用於治疗剂缓释的胃驻留系统及其使用方法 |
| WO2017100367A1 (en) | 2015-12-08 | 2017-06-15 | Lyndra, Inc. | Geometric configurations for gastric residence systems |
| AU2017268840B2 (en) | 2016-05-27 | 2022-02-10 | Lyndra Therapeutics, Inc. | Materials architecture for gastric residence systems |
| WO2018064630A1 (en) | 2016-09-30 | 2018-04-05 | Lyndra, Inc. | Gastric residence systems for sustained delivery of adamantane-class drugs |
| US11534404B2 (en) * | 2016-10-06 | 2022-12-27 | Sucampo Ag | Multilayer beads for pharmaceutical use |
| CA3066658A1 (en) | 2017-06-09 | 2018-12-13 | Lyndra, Inc. | Gastric residence systems with release rate-modulating films |
| WO2019025869A1 (en) * | 2017-07-31 | 2019-02-07 | Teva Pharmaceutical Industries Limited | GALENIC FORMS WITH CONTROLLED RELEASE MANUFACTURED IN ADDITIVE MANNER |
| CA3086153A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release |
| US11337920B2 (en) | 2017-12-18 | 2022-05-24 | Tris Pharma, Inc. | Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release |
| CA3085941A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
| JP7000148B2 (ja) * | 2017-12-27 | 2022-01-19 | 日本化薬株式会社 | ダサチニブを有効成分とする医薬組成物 |
| EP4013401A4 (en) | 2019-08-12 | 2023-07-12 | Massachusetts Institute of Technology | Articles and methods for administration of therapeutic agents |
| TWI763036B (zh) * | 2020-09-14 | 2022-05-01 | 王子賓 | 可膨脹微膠囊 |
| BR112023018524A2 (pt) | 2021-03-15 | 2023-11-21 | Epitomee Medical Ltd | Dispositivos expansíveis para entrega de agentes ativos aos tecidos |
| KR20250112750A (ko) | 2022-09-21 | 2025-07-24 | 이피토미 메디칼 엘티디 | 제어 가능하게 붕해될 수 있는 자체-확장가능한 섭취형 디바이스 |
| NL2033549B1 (en) * | 2022-11-17 | 2024-05-28 | Taiwan Mercury Medical Corp | Metformin tablet for relieving pain and reducing inflammation and manufacturing method thereof |
| AU2024265092A1 (en) * | 2023-05-03 | 2025-11-20 | Dark Canyon Laboratories, Llc | A floating drug delivery system for solid forms of salts used in bowel cleansing products |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5512411B2 (enExample) * | 1974-03-12 | 1980-04-02 | ||
| JPS5134879A (en) * | 1974-09-19 | 1976-03-24 | Eisai Co Ltd | Bishochukuryushinoseizoho |
| US5002772A (en) * | 1988-05-31 | 1991-03-26 | Pfizer Inc. | Gastric retention system for controlled drug release |
| NZ233403A (en) * | 1989-04-28 | 1992-09-25 | Mcneil Ppc Inc | Simulated capsule-like medicament |
| JPH03101615A (ja) * | 1989-09-14 | 1991-04-26 | Sumitomo Pharmaceut Co Ltd | 胃内滞留型持続性製剤 |
| IT1246382B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5314696A (en) * | 1991-06-27 | 1994-05-24 | Paulos Manley A | Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor |
| UA60318C2 (uk) * | 1997-03-26 | 2003-10-15 | Янссен Фармацевтика Н.В. | Пілюля, яка має ядро, покрите протигрибковим агентом і полімером, та спосіб її виготовлення |
| SE9702533D0 (sv) * | 1997-07-01 | 1997-07-01 | Astra Ab | New oral formulation |
| US5895663A (en) * | 1997-07-31 | 1999-04-20 | L. Perrigo Company | Pseudoephedrine hydrochloride extended-release tablets |
| US6050796A (en) | 1998-05-18 | 2000-04-18 | General Motors Corporation | Vane pump |
| AU2001232020A1 (en) | 2000-02-09 | 2001-08-20 | West Pharmaceutical Services Drug Delivery And Clinical Research Centre Limited | Floating drug delivery composition |
| JP2002370970A (ja) * | 2001-06-12 | 2002-12-24 | Sanwa Kagaku Kenkyusho Co Ltd | 胃内浮遊型固形製剤及びその製造方法 |
| JP4426286B2 (ja) * | 2001-07-10 | 2010-03-03 | テバ ファーマシューティカル インダストリーズ リミティド | ０次、０次−二相性、上昇型又は下降型薬物放出のための薬物送達システム |
| US7763663B2 (en) * | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
| EP1574534A1 (en) * | 2004-03-11 | 2005-09-14 | Rohm And Haas Company | Polymer carriers and process |
-
2007
- 2007-09-03 CN CN200780032818XA patent/CN101511346B/zh not_active Expired - Fee Related
- 2007-09-03 ZA ZA200901162A patent/ZA200901162B/xx unknown
- 2007-09-03 US US12/439,775 patent/US8277843B2/en not_active Expired - Fee Related
- 2007-09-03 RU RU2009112396/15A patent/RU2420268C2/ru not_active IP Right Cessation
- 2007-09-03 EP EP07866696A patent/EP2068844A4/en not_active Withdrawn
- 2007-09-03 BR BRPI0716481-5A2A patent/BRPI0716481A2/pt not_active IP Right Cessation
- 2007-09-03 KR KR1020097006969A patent/KR20090065524A/ko not_active Ceased
- 2007-09-03 CA CA002661172A patent/CA2661172A1/en not_active Abandoned
- 2007-09-03 WO PCT/IN2007/000392 patent/WO2008062440A2/en not_active Ceased
- 2007-09-03 JP JP2009526263A patent/JP2010502591A/ja active Pending
- 2007-09-03 AU AU2007323018A patent/AU2007323018B2/en not_active Ceased
- 2007-09-03 MX MX2009002371A patent/MX2009002371A/es unknown
- 2007-09-04 CL CL200702562A patent/CL2007002562A1/es unknown
- 2007-09-04 AR ARP070103903A patent/AR062644A1/es not_active Application Discontinuation
-
2009
- 2009-02-19 IL IL197121A patent/IL197121A0/en unknown
- 2009-02-19 NO NO20090807A patent/NO20090807A/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010502591A5 (enExample) | ||
| RU2009112396A (ru) | Способ программируемой плавучей доставки | |
| ES2125848T3 (es) | Comprimidos bioadhesivos. | |
| ES2260253T3 (es) | Composicion farmaceutica oral de liberacion controlada y absorcion prolongada. | |
| ES2202652T3 (es) | Formulaciones farmaceuticas de liberacion retardada de droga. | |
| RU2238087C2 (ru) | Композиции контролируемого высвобождения, содержащие нимесулид | |
| JP2005513057A5 (enExample) | ||
| JP2007532689A (ja) | 医薬有効成分の遅延性かつ調節性放出のための微粒子経口ガレヌス製剤 | |
| AU2002321249B2 (en) | Pharmaceutical compositions containing terbinafin and use thereof | |
| JP2004534057A5 (enExample) | ||
| RU2010146173A (ru) | Композиции, включающие слабоосновные лекарственные вещества, и лекарственные формы с контролированным высвобождением | |
| KR101269829B1 (ko) | 위체류 약물전달 시스템을 이용한 서방성 제제 | |
| JP2011500552A (ja) | 胃腸障害を処置するための医薬用組み合わせおよび組成物 | |
| CN101636152A (zh) | 含有西洛他唑的控释制剂及其制备方法 | |
| JP2011500553A (ja) | ５−アミノサリチル酸またはその塩もしくは代謝産物の新規な結腸を標的とする調節放出性生体接着性製剤 | |
| RU2007111755A (ru) | Фармацевтические полидисперсные композиции, включающие микофенольную кислоту или микофенолят натрия, и комбинации композиций с рапамицином | |
| JP2010508353A (ja) | エルブシタビン薬学的組成物 | |
| JP2019529570A (ja) | ミドドリンの組成物およびその使用方法 | |
| RU2577164C2 (ru) | Таблетки с регулируемым по месту и времени высвобождением глюкокортикоида в желудочно-кишечном тракте | |
| TW202224672A (zh) | 胃滯留藥物劑型 | |
| JP2021152050A (ja) | フマル酸ジメチルを含む医薬ビーズ製剤 | |
| JP2009512699A5 (enExample) | ||
| CN103417544B (zh) | 甲氨叶酸复方制剂及其制备方法和用途 | |
| CN104379138B (zh) | 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合 | |
| CN101146521A (zh) | 提供包含纤维素和甲基丙烯酸衍生物包衣的口服药物输送系统 |